Clinical Insights
by Scott Houlton, CEO MLM Medical Labs
Why the Right Lab Partner Matters More Than You Think
Bringing a new drug to market has never been more expensive. Recent estimates place the cost at roughly $2–$3 billion to move a therapy from discovery through regulatory approval. A significant portion of that investment is tied up in clinical trials, particularly Phase II and Phase III studies involving large patient populations.
The purpose of these trials is clear: demonstrate safety and efficacy in the intended patient population. But from a business and operational perspective, there is another equally important objective—run the trial as efficiently and quickly as possible. Every delay increases development costs and reduces the period of market exclusivity during which a new therapy can deliver both patient benefit and financial return.
The High Stakes of Clinical Trials
Running a clinical trial that costs tens—or even hundreds—of millions of dollars is inherently stressful. The stakes extend far beyond the sponsor organization:
- ■ Patients are waiting for new treatments or potential cures.
- ■ Investors are expecting returns on significant capital investments.
- ■ Development teams know their professional reputations—and sometimes their jobs—are on the line.
When a trial fails, the consequences are substantial. Patients continue without access to new therapies, investors face disappointing outcomes, and years of work can vanish overnight.
Why Trials Fail (Even When the Drug Works)
Of course, some trials fail because the drug itself simply doesn’t work. No amount of operational excellence can change that reality.
But there are also many cases where promising therapies are delayed, divested, or abandoned due to avoidable operational failures within the trial itself.
Common issues include:
- ■ Drug formulation or stability problems
- ■ Packaging or labeling errors that risk unblinding or mis-dosing
- ■ Patient recruitment challenges
- ■ Poorly designed protocols
- ■ Inconsistent or unreliable laboratory data
Each of these can derail a study that otherwise had real therapeutic potential.
For this discussion, I want to focus on one factor that is often underestimated but critically important: choosing the right laboratory partner.
The Complex Ecosystem of a Clinical Trial
A successful clinical trial requires coordination across a large ecosystem of partners and functions:
- ■ The drug formulation must be stable and consistently manufactured.
- ■ The trial protocol must clearly define endpoints and study design.
- ■ Investigational materials must be sourced and packaged correctly.
- ■ Clinical operations teams must select sites and recruit patients—often with the support of a CRO.
- ■ A central laboratory partner must manage sample logistics and testing.
- ■ Data teams must aggregate and analyze results.
- ■ Regulatory experts must prepare submissions for agencies such as the FDA or EMA.
If all of these pieces align—and countless smaller details fall into place—the therapy can ultimately reach the market.
But at the center of this entire process sits one critical asset:
The clinical data.
The laboratory generates a large portion of the objective data that forms the backbone of the regulatory submission. If that data is delayed, inconsistent, or unreliable, the entire development program is at risk.
The Hidden Risk in Choosing the “Safe” Option
Many sponsors approach laboratory selection with a risk-avoidance mindset. The logic often sounds like this:
“Choose the biggest, most recognizable name. It’s the safest decision.”
On the surface, that reasoning feels sound—especially inside organizations where individuals want to minimize personal risk.
But in practice, this can be a costly mistake, particularly for small to mid-sized biopharma companies.
Large service providers are capable organizations, but they are often built for scale and standardization, not necessarily for speed, flexibility, or customized problem solving. Smaller sponsors frequently discover that their study becomes just one project among hundreds.
In contrast, the right partner—regardless of size—should bring:
- Operational agility
- Protocol flexibility
- Rapid issue resolution
- High-touch collaboration with the sponsor team
These characteristics can dramatically influence how smoothly a study runs.
Experience from the Field
Over the past 25 years working across pharmaceutical development, I have worked with both large global service providers and smaller specialized organizations.
And I can point to dozens of situations where the “safe” choice—the largest or most recognizable provider—ultimately proved to be the wrong one.
Not because those organizations lacked capability, but because the fit between sponsor needs and service model was misaligned.
When that happens, the consequences show up quickly:
- Slow response times
- Rigid processes that cannot adapt to protocol changes
- Data delays that ripple through study timelines
- Escalating operational frustration
In clinical development, time is one of the most expensive resources you have. The wrong partner can quietly erode it.
Choosing Partners That Improve Trial Success
The reality is that outsourcing decisions are strategic decisions. The lab partner you select is not just a vendor performing tests—it is a critical contributor to the data integrity, timeline, and overall success of the trial.
Sponsors who approach laboratory selection strategically tend to ask questions like:
- How quickly can this partner adapt to protocol amendments?
- How responsive is their operational team?
- How well do they integrate with CROs and clinical sites?
- Do they prioritize collaboration and transparency?
- Are they structured to move quickly when problems arise?
These factors often matter far more than brand recognition alone.
Final Thought
Clinical trials are complex, high-risk endeavors. While scientific uncertainty is unavoidable, operational failures should not be.
Selecting the right partners—especially your laboratory partner—can make the difference between a study that moves efficiently toward approval and one that becomes delayed, derailed, or unnecessarily expensive.
In an industry where patient outcomes come first and billions of dollars depend on getting it right, decisions like this deserve far more scrutiny than they often receive.
Share this:
Facebook
X
LinkedIn
